Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: S100A12

Gene summary for S100A12

Gene summary.

Gene information	Species	Human
	Gene symbol	S100A12
	Gene ID	6283
	Gene name	S100 calcium binding protein A12
	Gene Alias	CAAF1
	Cytomap	1q21.3
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	P80511

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
6283	S100A12	C04	Human	Oral cavity	OSCC	1.15e-02	2.74e-01	0.2633
6283	S100A12	C21	Human	Oral cavity	OSCC	9.76e-08	1.74e+00	0.2678
6283	S100A12	C57	Human	Oral cavity	OSCC	5.57e-47	1.50e+00	0.1679
6283	S100A12	LP15	Human	Oral cavity	LP	8.49e-04	8.04e-01	0.2174
6283	S100A12	SYSMH3	Human	Oral cavity	OSCC	4.31e-04	1.58e-01	0.2442
6283	S100A12	SYSMH5	Human	Oral cavity	OSCC	1.57e-22	4.45e-01	0.0647

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004312218	Oral cavity	OSCC	regulation of I-kappaB kinase/NF-kappaB signaling	155/7305	249/18723	7.79e-14	4.14e-12	155
GO:004312310	Oral cavity	OSCC	positive regulation of I-kappaB kinase/NF-kappaB signaling	122/7305	186/18723	1.68e-13	8.52e-12	122
GO:000724910	Oral cavity	OSCC	I-kappaB kinase/NF-kappaB signaling	169/7305	281/18723	4.69e-13	2.25e-11	169
GO:007190010	Oral cavity	OSCC	regulation of protein serine/threonine kinase activity	201/7305	359/18723	3.90e-11	1.27e-09	201
GO:00434054	Oral cavity	OSCC	regulation of MAP kinase activity	101/7305	177/18723	8.13e-07	1.12e-05	101
GO:00510907	Oral cavity	OSCC	regulation of DNA-binding transcription factor activity	221/7305	440/18723	9.06e-07	1.23e-05	221
GO:004586016	Oral cavity	OSCC	positive regulation of protein kinase activity	194/7305	386/18723	3.90e-06	4.59e-05	194
GO:003367418	Oral cavity	OSCC	positive regulation of kinase activity	228/7305	467/18723	8.31e-06	8.90e-05	228
GO:00719028	Oral cavity	OSCC	positive regulation of protein serine/threonine kinase activity	107/7305	200/18723	2.12e-05	2.02e-04	107
GO:00510917	Oral cavity	OSCC	positive regulation of DNA-binding transcription factor activity	134/7305	260/18723	2.52e-05	2.35e-04	134
GO:000941018	Oral cavity	OSCC	response to xenobiotic stimulus	222/7305	462/18723	4.00e-05	3.48e-04	222
GO:00510925	Oral cavity	OSCC	positive regulation of NF-kappaB transcription factor activity	82/7305	152/18723	1.28e-04	9.13e-04	82
GO:00321037	Oral cavity	OSCC	positive regulation of response to external stimulus	203/7305	427/18723	1.79e-04	1.22e-03	203
GO:005090010	Oral cavity	OSCC	leukocyte migration	176/7305	369/18723	3.80e-04	2.31e-03	176
GO:00603269	Oral cavity	OSCC	cell chemotaxis	146/7305	310/18723	2.13e-03	9.80e-03	146
GO:00305959	Oral cavity	OSCC	leukocyte chemotaxis	110/7305	230/18723	3.86e-03	1.58e-02	110
GO:00434062	Oral cavity	OSCC	positive regulation of MAP kinase activity	58/7305	112/18723	4.01e-03	1.64e-02	58
GO:00434107	Oral cavity	OSCC	positive regulation of MAPK cascade	213/7305	480/18723	8.71e-03	3.16e-02	213
GO:007162110	Oral cavity	OSCC	granulocyte chemotaxis	62/7305	125/18723	1.02e-02	3.52e-02	62
GO:00313495	Oral cavity	OSCC	positive regulation of defense response	127/7305	278/18723	1.32e-02	4.39e-02	127

Page: 1 2

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

S100A12

insertion

Nonsense_Mutation

novel

c.129_130insCAGGTCAAGCCTTGTTAATTCCAGGGTGGTTCATG

p.Thr44GlnfsTer6

p.T44Qfs*6

P80511

protein_coding

TCGA-A7-A0CE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

S100A12

insertion

Frame_Shift_Ins

novel

c.118_119insTCCTTTGCTTCCCTCTCTCAATAACTCACTTAAGGCTCTACTC

p.Glu40ValfsTer26

p.E40Vfs*26

P80511

protein_coding

TCGA-AO-A0JB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

S100A12

SNV

Missense_Mutation

rs761048858

c.208G>A

p.Asp70Asn

p.D70N

P80511

protein_coding

tolerated(0.43)

benign(0.006)

TCGA-AX-A2HD-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

III/IV

Unknown

S100A12

SNV

Missense_Mutation

c.146A>C

p.Lys49Thr

p.K49T

P80511

protein_coding

deleterious(0.01)

possibly_damaging(0.848)

TCGA-B5-A0JY-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

S100A12

SNV

Missense_Mutation

novel

c.105N>T

p.Gln35His

p.Q35H

P80511

protein_coding

tolerated(0.05)

probably_damaging(0.963)

TCGA-B5-A1MR-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

III/IV

Unknown

S100A12

SNV

Missense_Mutation

c.124N>A

p.Ala42Thr

p.A42T

P80511

protein_coding

tolerated(0.09)

benign(0.133)

TCGA-BS-A0TJ-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

S100A12

SNV

Missense_Mutation

novel

c.260A>C

p.Tyr87Ser

p.Y87S

P80511

protein_coding

deleterious(0.04)

benign(0)

TCGA-EY-A1G8-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

S100A12

SNV

Missense_Mutation

c.68N>A

p.Gly23Glu

p.G23E

P80511

protein_coding

deleterious(0.03)

probably_damaging(0.957)

TCGA-95-7562-01

Lung

lung adenocarcinoma

Male

>=65

I/II

Chemotherapy

cisplatin

S100A12

SNV

Missense_Mutation

novel

c.232G>T

p.Val78Leu

p.V78L

P80511

protein_coding

tolerated(0.15)

benign(0)

TCGA-90-7964-01

Lung

lung squamous cell carcinoma

Male

>=65

I/II

Unknown

S100A12

SNV

Missense_Mutation

novel

c.55T>A

p.Ser19Thr

p.S19T

P80511

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-P3-A6T4-01

Oral cavity

head & neck squamous cell carcinoma

Male

<65

I/II

Unknown

Page: 1

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
6283	S100A12	DRUGGABLE GENOME, KINASE		Atogepant	ATOGEPANT
6283	S100A12	DRUGGABLE GENOME, KINASE		MTX	METHOTREXATE	15077313
6283	S100A12	DRUGGABLE GENOME, KINASE		METHOTREXATE	METHOTREXATE	15077313
6283	S100A12	DRUGGABLE GENOME, KINASE		Eptinezumab	EPTINEZUMAB
6283	S100A12	DRUGGABLE GENOME, KINASE		BMS-927711	RIMEGEPANT
6283	S100A12	DRUGGABLE GENOME, KINASE		MK-1602	UBROGEPANT

Page: 1